{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T11:58:52Z","timestamp":1786190332497,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274005"],"award-info":[{"award-number":["82274005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773807"],"award-info":[{"award-number":["81773807"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["SDU-21036"],"award-info":[{"award-number":["SDU-21036"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ijantimicag.2024.107209","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T06:22:09Z","timestamp":1715926929000},"page":"107209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["The effect of malaria-induced alteration of metabolism on piperaquine disposition in Plasmodium yoelii infected mice and predicted in malaria patients"],"prefix":"10.1016","volume":"64","author":[{"given":"Yuewu","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7911-9906","authenticated-orcid":false,"given":"Jie","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2024.107209_bib0001","series-title":"Guidelines for malaria","year":"2023"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0002","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","article-title":"Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial","volume":"395","author":"van der Pluijm","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0003","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/17425255.2017.1391212","article-title":"Pharmacokinetic considerations for use of artemisinin-based combination therapies against falciparum malaria in different ethnic populations","volume":"13","author":"Sugiarto","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0004","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/1389200221999210101232057","article-title":"Malaria-induced alterations of drug kinetics and metabolism in rodents and humans","volume":"22","author":"De-Oliveira","year":"2021","journal-title":"Current Drug Metab"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.curtheres.2019.100567","article-title":"Pharmacokinetic parameters of quinine in healthy subjects and in patients with uncomplicated malaria in Nigeria: analysis of data using a population approach","volume":"91","author":"Adehin","year":"2019","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0006","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1093\/jac\/dku228","article-title":"Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda","volume":"69","author":"Kloprogge","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0007","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/jac\/dku430","article-title":"Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria","volume":"70","author":"Reuter","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0008","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1475-2875-9-81","article-title":"Up- and down-modulation of liver cytochrome P450 activities and associated events in two murine malaria models","volume":"9","author":"De-Oliveira","year":"2010","journal-title":"Malar J"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0009","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12936-019-2860-5","article-title":"A non-lethal malarial infection results in reduced drug metabolizing enzyme expression and drug clearance in mice","volume":"18","author":"Mimche","year":"2019","journal-title":"Malar J"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0010","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF03190365","article-title":"Effects of Plasmodium berghei infection on cytochromes P-450 2E1 and 3A2","volume":"24","author":"Uhl","year":"1999","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0011","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejphar.2009.05.030","article-title":"Malaria downmodulates mRNA expression and catalytic activities of CYP1A2, 2E1 and 3A11 in mouse liver","volume":"616","author":"Carvalho","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0012","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.exppara.2009.04.003","article-title":"Plasmodium yoelii: adverse outcome of non-lethal P. yoelii malaria during co-infection with Schistosoma mansoni in BALB\/c mouse model","volume":"122","author":"Sangweme","year":"2009","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0013","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/aps.2013.120","article-title":"Stereoselective binding of doxazosin enantiomers to plasma proteins from rats, dogs and humans in vitro","volume":"34","author":"Sun","year":"2013","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0014","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0168-8278(05)80151-5","article-title":"Nicardipine increases hepatic blood flow and the hepatic clearance of indocyanine green in patients with cirrhosis","volume":"20","author":"Garc\u00eda-Pag\u00e1n","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0015","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1080\/00498254.2019.1664791","article-title":"Predicting successful\/unsuccessful extrapolation for in vivo total clearance of model compounds with a variety of hepatic intrinsic metabolism and protein bindings in humans from pharmacokinetic data using chimeric mice with humanised liver","volume":"50","author":"Sawada","year":"2020","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0016","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/MAJ.0b013e31826caf12","article-title":"A standardized technique for the blood sedimentation test","volume":"346","author":"Wintrobe","year":"2013","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0017","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ymeth.2011.01.006","article-title":"Triton X-114 phase separation in the isolation and purification of mouse liver microsomal membrane proteins","volume":"54","author":"Mathias","year":"2011","journal-title":"Methods"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0018","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0019","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1124\/dmd.120.000152","article-title":"Scaling factors for clearance in adult liver cirrhosis","volume":"48","author":"El-Khateeb","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0020","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00228-003-0636-9","article-title":"Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data","volume":"59","author":"Li","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0021","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1124\/dmd.112.045765","article-title":"Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes","volume":"40","author":"Xing","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0022","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1124\/dmd.120.000306","article-title":"Metabolic retroversion of piperaquine (PQ) via hepatic cytochrome P450-mediated N-oxidation and reduction: not an important contributor to the prolonged elimination of PQ","volume":"49","author":"Xie","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00260-18","article-title":"Metabolism of piperaquine to its antiplasmodial metabolites and their pharmacokinetic profiles in healthy volunteers","volume":"62","author":"Liu","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0024","series-title":"Studies on pharmacokinetics and bioequivalence of dihydroartemisinin and piperaquine phosphate tablets with parallel design","author":"Huang","year":"2013"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/138920007779315053","article-title":"Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver","volume":"8","author":"Barter","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0026","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00228-010-0804-7","article-title":"Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria","volume":"66","author":"Ashley","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0027","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1365-2125.2003.02004.x","article-title":"Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria","volume":"57","author":"Hung","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0028","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5414\/CPP39025","article-title":"Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis","volume":"39","author":"Lelou\u00ebt","year":"2001","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0029","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/hep.510270217","article-title":"Cytochrome P4502A6 (CYP2A6) expression in human hepatocellular carcinoma","volume":"27","author":"Raunio","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0030","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/jpet.103.060111","article-title":"Endoplasmic reticulum stress due to altered cellular redox status positively regulates murine hepatic CYP2A5 expression","volume":"308","author":"Gilmore","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0031","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0006-291X(02)00196-1","article-title":"Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response","volume":"293","author":"Beigneux","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0032","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1124\/dmd.113.053850","article-title":"Role of constitutive androstane receptor in Toll-like receptor-mediated regulation of gene expression of hepatic drug-metabolizing enzymes and transporters","volume":"42","author":"Shah","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0033","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1042\/cs0820063","article-title":"Hepatic blood flow and metabolism in severe falciparum malaria: clearance of intravenously administered galactose","volume":"82","author":"Pukrittayakamee","year":"1992","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0034","doi-asserted-by":"crossref","first-page":"614","DOI":"10.4269\/ajtmh.2001.65.614","article-title":"Factors contributing to anemia after uncomplicated falciparum malaria","volume":"65","author":"Price","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0035","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1021\/acsinfecdis.9b00527","article-title":"Plasmodium falciparum artemisinin resistance: the effect of heme, protein damage, and parasite cell stress response","volume":"6","author":"Rosenthal","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0036","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1186\/s12879-019-4647-2","article-title":"Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous artesunate or quinine plus dihydroartemisinin-piperaquine","volume":"19","author":"Byakika-Kibwika","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0037","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/cpt.1534","article-title":"Reduced exposure to piperaquine, compared to adults, in young children receiving dihydroartemisinin-piperaquine as malaria chemoprevention","volume":"106","author":"Whalen","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0038","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/jcph.294","article-title":"Predicting the \"first dose in children\" of CYP3A-metabolized drugs: evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages","volume":"54","author":"Strougo","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0039","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s11095-010-0049-2","article-title":"Physiological modeling to understand the impact of enzymes and transporters on drug and metabolite data and bioavailability estimates","volume":"27","author":"Sun","year":"2010","journal-title":"Pharm Res"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0040","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2174\/1389200221999210101233340","article-title":"Physiologically-based pharmacokinetic (PBPK) modelling of transporter mediated drug absorption, clearance and drug-drug interactions","volume":"22","author":"Taskar","year":"2021","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcoa.2022.100042","article-title":"Determination of unbound piperaquine in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry","volume":"2","author":"Huang","year":"2022","journal-title":"J Chromatogr Open"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0042","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01427-22","article-title":"Efavirenz-based antiretroviral therapy but not pregnancy increased unbound piperaquine exposure in women during malaria chemoprevention","volume":"67","author":"Hong","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2019.117158","article-title":"Spectroscopic methodologies and molecular docking studies on the interaction of antimalarial drug piperaquine and its metabolites with human serum albumin","volume":"222","author":"Ma","year":"2019","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0044","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1016\/j.bcp.2007.03.011","article-title":"Activity of piperaquine and other 4-aminoquinoline antiplasmodial drugs against chloroquine-sensitive and resistant blood-stages of Plasmodium falciparum. Role of beta-haematin inhibition and drug concentration in vacuolar water- and lipid-phases","volume":"73","author":"Warhurst","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0045","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s12272-018-1012-8","article-title":"Development of a simultaneous LC-MS\/MS method to predict in vivo drug-drug interaction in mice","volume":"41","author":"Jo","year":"2018","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0046","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00204-012-0902-7","article-title":"A dual function of the furanocoumarin chalepensin in inhibiting Cyp2a and inducing Cyp2b in mice: the protein stabilization and receptor-mediated activation","volume":"86","author":"Lo","year":"2012","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.ijantimicag.2024.107209_bib0047","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/00498250412331285463","article-title":"Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison","volume":"34","author":"L\u00f6fgren","year":"2004","journal-title":"Xenobiotica"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924001274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924001274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:38:46Z","timestamp":1778513926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924001274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0924857924001274"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107209","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of malaria-induced alteration of metabolism on piperaquine disposition in Plasmodium yoelii infected mice and predicted in malaria patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107209"}}